These medications should not be taken with Zepbound
Hur J, Sullivan KA, Callaghan BC, Pop-Busui R, Feldman EL
PMC 4084638
GLP-1R agonists effects on cardiovascular events The first pieces of evidence of the potential clinical benefit of GLP-1 agonists have emerged recently, pointing to a decrease of major adverse cardiovascular and cerebrovascular events (MACCE) including stroke, MI, cardiac mortality, acute coronary syndrome, and revascularization procedures
Specifically, Keytruda was approved in combination with chemotherapy to treat adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy